View in EDS HTML Full Text PDF Full Text

Efficacy and safety of durcabtagene autoleucel in a phase 1 trial for patients with relapsed/refractory multiple myeloma.

Saved in:
Bibliographic Details
Title: Efficacy and safety of durcabtagene autoleucel in a phase 1 trial for patients with relapsed/refractory multiple myeloma.
Authors: Sperling AS; Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Division of Hematology, Brigham and Women's Hospital, Boston, MA 02115, USA.; Division of Hematology, Stanford University, Palo Alto, CA 94305, USA., Derman BA; Section of Hematology/Oncology, University of Chicago Medical Center, Chicago, IL 60637, USA., Nikiforow S; Dana-Farber Cancer Institute, Boston, MA 02215, USA., Alonso A; Dana-Farber Cancer Institute, Boston, MA 02215, USA., Ikegawa S; Dana-Farber Cancer Institute, Boston, MA 02215, USA., Orwitz N; Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936, USA., Quinn DS; Novartis BioMedical Research, Cambridge, MA 02139, USA., Pearson D; Novartis BioMedical Research, Basel 4056, Switzerland., Bu D; Novartis BioMedical Research, Cambridge, MA 02139, USA., Milanez-Almeida P; Novartis BioMedical Research, Cambridge, MA 02139, USA., Mataraza J; Novartis BioMedical Research, Cambridge, MA 02139, USA., Nadeem O; Dana-Farber Cancer Institute, Boston, MA 02215, USA., Liegel J; Beth Israel Deaconess Medical Center, Boston, MA 02215, USA., D'Souza A; Medical College of Wisconsin, Milwaukee, WI 53226, USA., Charles A; Novartis BioMedical Research, Cambridge, MA 02139, USA., Credi M; Novartis BioMedical Research, Cambridge, MA 02139, USA., Ritz J; Dana-Farber Cancer Institute, Boston, MA 02215, USA., Jakubowiak AJ; Section of Hematology/Oncology, University of Chicago Medical Center, Chicago, IL 60637, USA., De Vita S; Novartis BioMedical Research, Cambridge, MA 02139, USA., Munshi NC; Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Source: Science translational medicine [Sci Transl Med] 2026 May 27; Vol. 18 (851), pp. eadx1799. Date of Electronic Publication: 2026 May 27.
Publication Type: Journal Article; Clinical Trial, Phase I
Journal Info: Publisher: American Association for the Advancement of Science Country of Publication: United States NLM ID: 101505086 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1946-6242 (Electronic) Linking ISSN: 19466234 NLM ISO Abbreviation: Sci Transl Med Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42202046
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Efficacy and safety of durcabtagene autoleucel in a phase 1 trial for patients with relapsed/refractory multiple myeloma.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Sperling+AS%22">Sperling AS</searchLink>; Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Division of Hematology, Brigham and Women's Hospital, Boston, MA 02115, USA.; Division of Hematology, Stanford University, Palo Alto, CA 94305, USA.<br /><searchLink fieldCode="AU" term="%22Derman+BA%22">Derman BA</searchLink>; Section of Hematology/Oncology, University of Chicago Medical Center, Chicago, IL 60637, USA.<br /><searchLink fieldCode="AU" term="%22Nikiforow+S%22">Nikiforow S</searchLink>; Dana-Farber Cancer Institute, Boston, MA 02215, USA.<br /><searchLink fieldCode="AU" term="%22Alonso+A%22">Alonso A</searchLink>; Dana-Farber Cancer Institute, Boston, MA 02215, USA.<br /><searchLink fieldCode="AU" term="%22Ikegawa+S%22">Ikegawa S</searchLink>; Dana-Farber Cancer Institute, Boston, MA 02215, USA.<br /><searchLink fieldCode="AU" term="%22Orwitz+N%22">Orwitz N</searchLink>; Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936, USA.<br /><searchLink fieldCode="AU" term="%22Quinn+DS%22">Quinn DS</searchLink>; Novartis BioMedical Research, Cambridge, MA 02139, USA.<br /><searchLink fieldCode="AU" term="%22Pearson+D%22">Pearson D</searchLink>; Novartis BioMedical Research, Basel 4056, Switzerland.<br /><searchLink fieldCode="AU" term="%22Bu+D%22">Bu D</searchLink>; Novartis BioMedical Research, Cambridge, MA 02139, USA.<br /><searchLink fieldCode="AU" term="%22Milanez-Almeida+P%22">Milanez-Almeida P</searchLink>; Novartis BioMedical Research, Cambridge, MA 02139, USA.<br /><searchLink fieldCode="AU" term="%22Mataraza+J%22">Mataraza J</searchLink>; Novartis BioMedical Research, Cambridge, MA 02139, USA.<br /><searchLink fieldCode="AU" term="%22Nadeem+O%22">Nadeem O</searchLink>; Dana-Farber Cancer Institute, Boston, MA 02215, USA.<br /><searchLink fieldCode="AU" term="%22Liegel+J%22">Liegel J</searchLink>; Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.<br /><searchLink fieldCode="AU" term="%22D'Souza+A%22">D'Souza A</searchLink>; Medical College of Wisconsin, Milwaukee, WI 53226, USA.<br /><searchLink fieldCode="AU" term="%22Charles+A%22">Charles A</searchLink>; Novartis BioMedical Research, Cambridge, MA 02139, USA.<br /><searchLink fieldCode="AU" term="%22Credi+M%22">Credi M</searchLink>; Novartis BioMedical Research, Cambridge, MA 02139, USA.<br /><searchLink fieldCode="AU" term="%22Ritz+J%22">Ritz J</searchLink>; Dana-Farber Cancer Institute, Boston, MA 02215, USA.<br /><searchLink fieldCode="AU" term="%22Jakubowiak+AJ%22">Jakubowiak AJ</searchLink>; Section of Hematology/Oncology, University of Chicago Medical Center, Chicago, IL 60637, USA.<br /><searchLink fieldCode="AU" term="%22De+Vita+S%22">De Vita S</searchLink>; Novartis BioMedical Research, Cambridge, MA 02139, USA.<br /><searchLink fieldCode="AU" term="%22Munshi+NC%22">Munshi NC</searchLink>; Dana-Farber Cancer Institute, Boston, MA 02215, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101505086%22">Science translational medicine</searchLink> [Sci Transl Med] 2026 May 27; Vol. 18 (851), pp. eadx1799. <i>Date of Electronic Publication: </i>2026 May 27.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase I
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Association+for+the+Advancement+of+Science%22">American Association for the Advancement of Science </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101505086 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1946-6242 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2219466234%22">19466234 </searchLink><i>NLM ISO Abbreviation: </i>Sci Transl Med <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42202046
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1126/scitranslmed.adx1799
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: eadx1799
    Titles:
      – TitleFull: Efficacy and safety of durcabtagene autoleucel in a phase 1 trial for patients with relapsed/refractory multiple myeloma.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Sperling AS
      – PersonEntity:
          Name:
            NameFull: Derman BA
      – PersonEntity:
          Name:
            NameFull: Nikiforow S
      – PersonEntity:
          Name:
            NameFull: Alonso A
      – PersonEntity:
          Name:
            NameFull: Ikegawa S
      – PersonEntity:
          Name:
            NameFull: Orwitz N
      – PersonEntity:
          Name:
            NameFull: Quinn DS
      – PersonEntity:
          Name:
            NameFull: Pearson D
      – PersonEntity:
          Name:
            NameFull: Bu D
      – PersonEntity:
          Name:
            NameFull: Milanez-Almeida P
      – PersonEntity:
          Name:
            NameFull: Mataraza J
      – PersonEntity:
          Name:
            NameFull: Nadeem O
      – PersonEntity:
          Name:
            NameFull: Liegel J
      – PersonEntity:
          Name:
            NameFull: D'Souza A
      – PersonEntity:
          Name:
            NameFull: Charles A
      – PersonEntity:
          Name:
            NameFull: Credi M
      – PersonEntity:
          Name:
            NameFull: Ritz J
      – PersonEntity:
          Name:
            NameFull: Jakubowiak AJ
      – PersonEntity:
          Name:
            NameFull: De Vita S
      – PersonEntity:
          Name:
            NameFull: Munshi NC
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 27
              M: 05
              Text: 2026 May 27
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1946-6242
          Numbering:
            – Type: volume
              Value: 18
            – Type: issue
              Value: 851
          Titles:
            – TitleFull: Science translational medicine
              Type: main
ResultId 1